Actively Recruiting
An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Led by PepGen Inc · Updated on 2026-03-30
48
Participants Needed
3
Research Sites
157 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.
CONDITIONS
Official Title
An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant has completed a prior study with PGN-EDODM1
You will not qualify if you...
- Abnormal laboratory tests at screening considered clinically significant by the Investigator
- Use of an investigational drug (other than PGN-EDODM1), device, or product, within 30 days or 5 half-lives of the study drug (whichever is longer) prior to study entry
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
University of Calgary
Calgary, Alberta, Canada, T2N 4Z6
Actively Recruiting
2
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Actively Recruiting
3
CIUSSS du Saguenay-Lac-Saint-Jean
Saguenay, Canada
Actively Recruiting
Research Team
P
PepGen Patient Advocacy
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here